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ABSTRACT: Clearance concepts were introduced into the pharmacokinetics discipline in the 1970s and since
then have played a major role in characterization of the pharmacokinetic behavior of drugs. These concepts are
based on the relationship between organ extraction ratio or clearance and physiologic parameters such as the organ
blood flow and the intrinsic capability of the eliminating organ to remove the free (unbound) drug from the body.
Several theoretical models have been developed, which define these relationships and may be used to predict the
effects of changes in the physiological parameters on various pharmacokinetic parameters of drugs, such as drug
clearance. In this communication, the fundamentals of the two most widely used models of hepatic metabolism,
namely the well-stirred (venous equilibrium) and parallel-tube (sinusoidal perfusion) models, are reviewed.
Additionally, the assumptions inherent to these models and the differences between them in terms of their
predictive behavior are discussed. The effects of changes in the physiologic determinants of clearance on the blood
concentration-time profiles of drugs with low and high extraction ratio are also presented using numerical
examples. Lastly, interesting and unusual examples from the literature are provided where these concepts have
been applied beyond their widely known applications. These examples include estimation of the oral
bioavailability of drugs in the absence of otherwise needed intravenous data, differentiation between the role of
liver and gut in the first-pass loss of drugs, and distinction between the incomplete absorption and first-pass
metabolism in the gastrointestinal tract after the oral administration of drugs. It is concluded that the clearance
concepts are a powerful tool in explaining the pharmacokinetics of drugs and predicting the changes in their blood
concentration-time courses when the underlying physiologic parameters are altered due to age, disease states, or
drug interactions.
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For
Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.

__________________________________________________________________________________
INTRODUCTION

eliminating organ to remove the free drug from the
body (Cl’int), and the organ blood flow (Q). Since the
1970s, the clearance concepts have been widely used
in the literature to explain the pharmacokinetic
behavior of many drugs and the effects of changes in
the physiological parameters, as a result of disease
states, drug-drug interactions, or age, on the blood
concentration-time courses of drugs after different
routes of administration. The purpose of this
communication is to 1) briefly review the
fundamental principles of clearance concepts and 2)
_________________________________________

Clearance concepts were introduced into the
pharmacokinetics discipline in the 1970s by Gillette
(1), Rowland et al. (2), and Wilkinson and Shand (3).
As elegantly described by Benet (4) in a tribute to Dr.
Rowland for his contributions in this area, many
experimental observations could not be explained by
the prevalent pharmacokinetic theories in the late
1960s and early 1970s before the introduction of
clearance concepts. In contrast to the heavy reliance
on mathematical relationships for description of the
pharmacokinetic behavior of drugs in pre-clearance
era, the clearance concepts were based on the
relationship between organ clearance and
physiologic parameters, such as drug free (unbound)
fraction in blood (fub), intrinsic capability of the
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to present examples of the application of clearance
concepts in interpretation of pharmacokinetic
behavior of drugs.

any flow limitations. In other words, this is the
hypothetical volume of blood the liver could clear
per unit of time if Qh were unlimited. As a general
rule, when Cl’int increases, both Eh and Clh will
increase.
3.
The blood flow (Qh): Qh affects Eh and Clh
differently. As the flow increases, the extraction of
the drug into the hepatocytes decreases (less time for
extraction). However, because Clh is a function of
both Eh and Qh (Equation 3), overall, an increase in
Qh results in an increase (less than proportional) in
Clh.

FUNDAMENTAL CONCEPTS
Organ Clearance
The concept of organ clearance and loss of drugs
across an organ of elimination have been described
in detail previously (5-7). Briefly, the clearance of an
eliminating organ (Cli) is the volume of blood
cleared of drug by that organ per unit of time, which
is defined by the following equation:
𝐶𝑙 = 𝑄 ∙ 𝐸

Effects of Physiologic Determinants of Eh and Clh
for High and Low Eh Drugs
The statements above are generally true for any drug
with any Eh . However, the extent by which each of
these three parameters (fub, Qh, and Cl’int) affects Eh
and Clh is dependent on the initial Eh of the drug. For
drugs with high metabolic capacity (such as
propranolol), Cl’int may potentially be several-fold
higher than the liver blood flow. Therefore, for these
drugs, Clh is limited by perfusion (Qh). Because of
high intrinsic metabolic capacity, these drugs have
high (close to 1) extraction ratios. At the other
extreme, there are drugs for which Cl’int is much less
than Qh. Therefore, Clh of these drugs is limited by
their Cl’int. These drugs have low Eh (close to zero).

(1)

where Ei is the organ extraction ratio or the fraction
of the drug, which is eliminated by the organ during
one passage, and Qi represents the blood flow to the
organ. The 𝐸 value may be estimated from the
steady state concentration of drug entering (Cin) and
exiting (Cout) the eliminating organ, as shown in
Equation 2:
𝐸 =

(2)

For hepatic clearance (Clh), Equation 1 may be
rewritten in terms of hepatic extraction ratio (Eh) and
blood flow (Qh):
𝐶𝑙 = 𝑄 ∙ 𝐸

Models of Hepatic Clearance
There are different models that may be used to define
the relationship among physiologic parameters and
hepatic extraction ratio or clearance (8-15). Two of
the major models introduced in the 1970s, which are
still widely used, are the well-stirred (or venous
equilibrium) and parallel tube (or sinusoidal
perfusion) models (8-10). These two models are
graphically shown in Fig. 1. As shown in the figure,
the well-stirred model assumes that the eliminating
organ (liver) is a single well-stirred compartment,
with the free concentration of the drug in the blood
leaving the liver being in equilibrium with and equal
to the free drug concentration in the liver water. The
parallel-tube model assumes that the liver is
composed of identical parallel tubes with even
distribution of the enzymes along the length of the
tube, and that the blood concentration of free drug
decreases exponentially along the length of the tube
(Fig. 1). For the parallel-tube model, the average
concentration of the drug in the liver is estimated as
the logarithmic averages of the inlet (Cin) and outlet
(Cout) concentrations.

(3)

Because the lower and upper limits of Eh are zero and
1, the Clh of drugs could potentially range from zero
to Qh.
Physiologic Determinants of Eh and Clh
In the liver, drugs travel through the sinusoids and
come in contact with the hepatocytes, which contain
enzymes for drug metabolism. The drug in the
sinusoids may be in two forms of protein bound and
free. The extent of extraction (and clearance) of
drugs depends on at least 3 factors described below.
1.
Free fraction of the drug in blood (fub): It is
generally assumed that only the free drug may enter
the hepatocytes, where it is subject to metabolism or
biliary excretion. As a general rule, the higher fub, the
larger are Eh and Clh.
2.
Intrinsic clearance of the free drug (Cl’int):
This parameter is the intrinsic capability of the liver
to remove the drug from the blood in the absence of
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In both models, the hepatic clearance (Clh) is
related to the hepatic blood flow (Qh) and the
extraction ratio (Eh) by Equation 3. Additionally, in
both models, hepatic availability (Fh), which is
defined by the
ratio, is related to Eh using the

𝐹 =1−𝐸 =1−

(4)

𝐶𝑙 = 𝑄 ×

As demonstrated in Equation 4, Fh is the fraction of
the drug escaping extraction by the liver. In other
words, it is the fraction of the concentration entering
the liver, which exits the liver intact.

∙
∙

∙

(6)

∙

(7)

∙

The 𝐶𝑙 parameter, which is an indication of the
intrinsic capability of the liver to remove the drug
from the body in the absence of any flow limitation,
is related to the sum of activities of the enzymes that
metabolize the drug:

Well-Stirred Model
For the well-stirred model, the relationships between
Eh or Fh and fub, Cl’int, and Qh are defined by the
following equations:
𝐸 =

=

∙

Therefore, based on the well-stirred model, Clh may
be defined in terms of its individual components
using the following equation:

following equation:
Fh = 1– Eh

∙

𝐶𝑙

=∑

,
,

,

(8)

(5)

Figure 1. Graphical representations of the well-stirred (top) and parallel-tube (bottom) models of organ clearance. Cin and
Cout represent concentration of the drug entering and leaving the liver, respectively, and the dashed lines indicate the unbound
concentration of the drug in the liver along the direction of flow. Adapted from reference (8).
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In the above equation, Vmax,i, Km,i, and CL,u refer to the
maximum velocity and Michaelis-Menten constant
of the individual enzymes involved in the
metabolism of the drug and the unbound
concentration of the drug in the liver, respectively. If
the drug is also subject to biliary excretion, Cl’int is
the summation of both metabolic and excretory
intrinsic clearances.
For simplicity, some investigators use Clint,
instead of the term 𝑓 ∙ 𝐶𝑙 , in Equations 5, 6 and
7:
𝐸 =
(9)

𝐸 =
𝐹 =

)

(≪

𝑓

≈

)

(16)

≈

(17)

≈1

≈𝑄 ×

≈ 𝐶𝑙

≈

(18)

∙ 𝐶𝑙

Examples of drugs with low Eh include warfarin,
tolbutamide,
diazepam,
erythromycin,
and
theophylline.
Parallel-Tube Model
For the parallel-tube model, the relationships
between Eh, Fh, or Clh and fub, Cl’int, and Qh are given
below:

(11)

𝐶𝑙 = 𝑄 ×

)

(≪

𝐶𝑙 = 𝑄 ×

(10)

𝐹 =

(≪

∙

𝐸 =1−𝑒
The term Clint is defined as the intrinsic clearance of
the total (free plus unbound) drug. Equation 9 may
be rearranged to estimate Clint when the Eh and Qh
values are known:

(19)

=1−𝑒
∙

𝐹 =1−𝐸 =𝑒

(20)

=𝑒
∙

𝐶𝑙

×

=

×

=

𝐶𝑙 = 𝑄 ∙ 𝐸 = 𝑄

(12)

𝑒

For drugs with high Eh (i.e., high values of Clint
relative to Qh), Equations 9, 10, and 11 would
simplify to the following equations:
𝐸 =

(≪

𝐹 =
𝐶𝑙 = 𝑄 ×

≈

)

(≪

(≪

≈1
≈

)

)

≈𝑄 ×

1−𝑒

=𝑄

1−

(21)

If Equation 19 or Equation 20 for the parallel tube
model is to be used for the estimation of Clint when
Eh and Qh are known, this may be done by taking the
natural logarithm of the exponential term:

(13)
(14)

ln(1 − 𝐸 ) =

≈𝑄

𝐶𝑙

(15)

(22)

= −𝑄 × ln(1 − 𝐸 ) = −𝑄 × ln𝐹

(23)

Similar to the well-stirred model, for drugs with
the very high or very low Eh, Equation 21 predicts
that the Clh is limited by Qh or Clint (𝑓 ∙ 𝐶𝑙 ),
respectively.

These approximate equations indicate that for drugs
with very high Eh (close to 1), Fh is proportionally
related to Qh and inversely related to 𝐶𝑙 .
Additionally, the Clh of these drugs is perfusionlimited. Examples of drugs with high Eh include
propranolol, verapamil, morphine, meperidine,
nitroglycerine, and lidocaine.
On the other hand, for drugs with low Eh (i.e.,
low values of Clint relative to Qh), Eh is directly
related to Clint and inversely related Qh, Fh is almost
close to 1, and Clh of the drug becomes almost equal
to Clint or 𝑓 ∙ 𝐶𝑙 :

For both models, the above equations assume
that the permeability of the drug across the interstitial
space and hepatocyte membranes is much higher
than the Cl’int of the drug. Therefore, permeability is
not the rate-limiting step in the elimination of the
drug. However, if permeability becomes an issue,
these equations need to be modified to account for
the permeability parameters. Pravastatin is an
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example of drugs with uptake permeability-limited
elimination (16).

demonstrated in Fig. 2, after oral administration, the
drug is absorbed from the gastrointestinal tract and
passes through the liver before reaching the systemic
circulation. This means the orally-administered drug
entering the systemic circulation has to pass through
the liver first (“first-pass effect”). This is different
from the intravenous administration, where the drug
is directly introduced into the systemic circulation
without passing through the liver first (Fig. 2).
Obviously, in both cases (intravenous and oral), after
reaching the systemic circulation, a fraction of the
drug will be passing through different organs,
including the liver, with each circulation. However,
the oral drug has one extra “pass” through the liver
during the absorption process. Therefore, the oral
bioavailability of drugs (F) is influenced by their
hepatic availability (Fh). In addition to Fh, F is also
affected by the loss of drug during the absorption
process such as incomplete absorption and/or
metabolism/degradation in the gastrointestinal tract
(Fig. 2). To clarify this, consider an example where
200 mg of a drug is administered orally to a patient.
Assume only 40% of the dose is absorbed orally
(fraction of the dose absorbed or Fab of 0.4), which
means only 80 mg reaches the enterocytes. If the
drug is subject to metabolism in the gut, resulting in
50% of the drug escaping metabolism in the
enterocytes (Fg of 0.5), only 40 mg of the drug
reaches the liver. Assuming a hepatic Eh of 0.7 (Fh or
hepatic availability of 0.3), 30% of the drug reaching
the liver will pass intact into the systemic circulation
(0.3 x 40 mg or 12 mg). This means that out of the
200-mg oral dose, only 12 mg reaches the systemic
circulation. Therefore, the oral bioavailability of this
drug (relative to intravenous administration), which
may be estimated experimentally by the oral AUC:
intravenous AUC ratio, is only 0.06 or 6% (12/200).
The following equation describes the relationship
among F, Fab, Fg, and Fh:

Differences between the Models in Predictions of
Pharmacokinetics of Drugs
Simulations have shown (8) that the two models
behave relatively close to each other with regard to
the effects of changes in fub and/or Cl’int (i.e., Clint).
However, the major difference between the two
models is with regard to their prediction of hepatic
availability (Fh) based on changes in Qh for the high
Eh dugs. Although the differences between the two
models for the prediction of Eh even at high Eh is
relatively small (30%), this translates to very large
differences between the two models in prediction of
Fh and oral AUC of drugs with high hepatic Eh (8).
This is because at high Eh, Fh changes linearly
relative to Qh for the well-stirred model as
demonstrated in Equation 14 ( 𝐹 ≈ 𝑄 ⁄𝐶𝑙 ).
However, for the parallel-tube model, Fh changes
exponentially relative to Qh, as demonstrated in
⁄
Equation 20 ( 𝐹 = 𝑒
). Therefore, at the
extreme Eh value of 0.99, the difference in prediction
of Fh for the two models may be over a thousand-fold
(8). Further experimental studies (9, 10) have
suggested that for most drugs, such as lidocaine, the
well-stirred model predicts the clearance of the drug
better. Therefore, most investigators use the wellstirred model in their analysis of hepatic clearance of
drugs, unless it is proven to be not applicable.
However, it has recently been argued that the studies
designed to distinguish between the two models are
inherently biased towards the well-stirred model (17),
a notion that is subject to debate (18) and outside the
scope of this review. Because of the prevalence of
the use of the well-stirred model in the literature, we
will use this model for the remainder of our
discussion and case studies presented here.
The Relationship between Hepatic Availability
(Fh) and Oral Bioavailability (F)
Figure 2 depicts the potential barriers for an oral dose
to reach systemic circulation, which may result in the
loss of drugs after their oral administration (19).
After the intravenous dosing, however, the drug is
introduced directly into the systemic circulation.
Therefore, the oral bioavailability of drugs (F), or the
extent by which an oral dose enters the systemic
circulation, is defined by the ratio of the blood AUCs
after the oral and intravenous administration. As

𝐹=𝐹

×𝐹 ×𝐹

(24)

𝐹 = 0.4 × 0.5 × 0.3 = 0.06
It should be noted that if the absorption of the
drug is complete and there is no gastrointestinal
metabolism (i.e., 𝐹 × 𝐹 = 1 ), the hepatic
availability and oral bioavailability would be the
same. In other words, the oral bioavailability of
drugs cannot be more than their hepatic availability.
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Figure 2. Barriers to drug entry into the systemic circulation after oral administration of drugs. For comparison, direct
introduction of the drug into the systemic circulation after intravenous administration is also shown. Abbreviations: Fab,
fraction of the dose absorbed; Fg, fraction of the dose escaping gut metabolism; Fh, fraction of the dose escaping liver
metabolism; Eg, gut extraction ratio; Eh, liver extraction ratio. Adapted from reference (19).

Effects of Qh, fub, and Cl’int on the Blood
Concentration-Time Courses of Low and High Eh
Drugs
After intravenous dosing, the only pharmacokinetic
parameter that affects the AUC of a drug is its
systemic Cl. However, after oral dosing, the AUC is
dependent on both the systemic Cl and oral
availability (F), both of which are subject to change
if fub, Cl’int, and/or Qh is changed. Here, we examine
the effects of a change in the determinants of Clh of
drugs on their blood concentration-time profiles for
the low and high Eh drugs. For simplicity, we assume
that the drug is eliminated by hepatic metabolism
only, which means the systemic Cl is equal to Clh.
Additionally, we assume that the oral absorption of
the drug is complete with no metabolism in the gut,
which means the oral availability of the drug (F) is
equal to its hepatic availability (Fh).

hypothetical drug. Additionally, Fh for this drug is
very high (almost 1) (Table 1). Assuming a volume
of distribution of 5 L, the half-life of the drug is 35 h
in Control subjects (Table 1). As demonstrated in
Table 1, the changes in either Cl’int or fub would
produce the same net effect on the other kinetic
parameters of the drug because they are both
reflected in the Clint value. A two-fold increase in
Cl’int or fub results in a two-fold increase in Clint, Eh,
and Clh for this low Eh drug (Table 1). Additionally,
a two-fold increase in Clh also results in a two-fold
decrease in the half-life of the drug (Table 1).
However, the Fh value of the drug remains close to 1,
regardless of the changes in fub or Cl’int (Table 1). As
demonstrated in Figs. 3A and 3B, a two-fold increase
in Clint for a low Eh drug results in an almost two-fold
increase in its Cl, which is demonstrated by a
corresponding two-fold decrease in the AUC and
half-life after both intravenous and oral dosing. An
example of such change is the effects of coadministration of warfarin, a low Eh drug, with
rifampin, which induces the metabolism of warfarin
(higher Cl’int), resulting in a higher clearance, lower
AUC, and a shorter half-life (20).
As for Qh, neither intravenous nor oral profile of
a low Eh drug is affected by a change in Qh (Figs. 3C
and 3D). Although a two-fold increase in Qh results
in a two-fold decrease in Eh, the Clh value remains
unchanged because the decrease in Eh is
compensated by a corresponding increase in Qh
(Table 1). This is consistent with the notion that the
Cl of a low Eh drugs is mostly dependent on fub and
Cl’int (Equation 18). Additionally, Fh of the drug is
very high regardless of the change in Qh (Table 1).

Low Extraction Ratio Drugs
The characteristics of a hypothetical drug with a very
low Eh value of 0.0011 under normal conditions and
when the Clint (Cl’int or fub) or Qh values are
increased by a factor of 2 are listed in Table 1.
Additionally,
the
corresponding
blood
concentration-time courses of the drug are presented
in Fig. 3. After selection of Cl’int and fub values for
this drug to generate a low Clint value (0.1 L/h)
relative to the hepatic blood flow (90 L/h), the Eh, Fh,
and Clh are calculated using Equations 9, 4, and 3,
respectively. As stated above, for a low Eh drug, Clh
is expected to be close to Clint or 𝑓 ∙ 𝐶𝑙 . This is
also shown in Table 1 for Control subjects, where the
Clint and Clh values are almost identical for this
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(A)

(B)

1

Concentration (mg/L)

10

Concentration (mg/L)

10

Low E-Control
Increased Clint
0

20

40

1

60

Time (Hours)

Low E-Control
Increased Clint
0

20

40

60

Time (Hours)

(C)

(D)
10

Concentration (mg/L)

Concentration (mg/L)

10

Low E-Control

1

Increased Qh
0

20

40

1

60

Low E-Control
Increased Qh
0

20

40

60

Time (Hours)

Time (Hours)

Figure 3. Effects of a two-fold increase in Clint (fub or Cl’int) (top panels) or Qh (bottom panels) on the blood concentrationtime courses of a hypothetical low Eh drug after intravenous (left) or oral (right) administration of a 50-mg dose of the drug.
The kinetic parameters are listed in Table 1.
Table 1. The pharmacokinetic parameters of a hypothetical drug a with low hepatic extraction ratio (Eh) in the absence
(Control) and presence of changes in the intrinsic capability of the liver to remove the free drug (Cl’int), free drug fraction
in blood (fub), or hepatic blood flow (Qh).
Condition
Cl’int
fub
Clint
Qh
Ehb
Fhb
Clhb
V
t1/2c
(L/h)
(L/h)
(L/h)
(L/h)
(L)
(h)
Control
10
0.01
0.10
90
0.00111
0.999
0.0999
5
34.7
20
0.01
0.20
90
0.00222
0.998
0.200
5
17.4
 Cl’int x 2
10
0.02
0.20
90
0.00222
0.998
0.200
5
17.4
 fub x 2
10
0.01
0.10
180
0.000555
0.999
0.0999
5
34.7
 Qh x 2
a
The hypothetical drug has a Cl’int of 10 L/h, a fub of 0.01, and a volume of distribution (V) of 5 L under baseline
conditions, with elimination through the liver only.
b
Eh, Fh, and Clh were estimated from the values of Cl’int, fub, and Qh using Equations 9, 4, and 3, respectively.
.
×
c
Half-life (t1/2) is estimated from 𝑡 / =
, where Cl is assumed to be equal to Clh.
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High Extraction Ratio Drugs
The pharmacokinetic characteristics of a high Eh
drug in the absence (Control) or presence of changes
in Cl’int, fub, or Qh are listed in Table 2. Additionally,
the corresponding blood concentration-time courses
are shown in Fig. 4. The Clint of the drug in Control
subjects (1500 L/h) is much more than the Qh of 90
L/h, hence a high Eh of 0.943 (Table 2). As expected,
the drug has a very low Fh value of 0.0566.
Additionally, assuming a V of 400 L, the drug has a
half-life of 3.26 h (Table 2). In contrast to the low Eh
drug (Table 1), doubling the Clint by doubling either
fub or Cl’int does not substantially affect the Eh, Clh,
or half-life of this high Eh drug (Table 2). The lack
of changes in the Clh of this high Eh drug after
doubling Clint is predictable because the Clh of these
drugs are mostly perfusion limited. However, the
hepatic availability (and oral bioavailability) of the
drug is reduced by almost 50% when Clint is
increased by a factor of 2 (Table 2). This is because
after oral dosing, the Fh of the high Eh drugs is almost
linearly (inversely) related to their Clint (Equation 14).
Consequently, whereas the blood concentration-time
courses of the high Eh drug after the intravenous
administration are insensitive to changes in Clint (no
change in Cl) (Fig. 4A), the Fh, blood concentrations,
and AUC of the drug after the oral administration are
reduced by an almost 50% in the presence of a twofold increase in Clint (Fig. 4B).
The above discussion clearly shows that the
disease states and/or drug interactions that affect
Cl’int and/or fub would be reflected in the blood
concentration-time courses of high Eh drugs only
after the oral dosing, but not after the intravenous
administration (Figs. 4A and 4B).
An example of such effect is the interaction
between the enzyme inducer pentobarbital and the
high Eh drug alprenolol reported by Alvan et al. (21).

In that study, a single dose of alprenolol was
administered intravenously or orally before and after
10-14 daily doses of pentobarbital. Whereas
pentobarbital reduced the AUC of the orallyadministered alprenolol by more than 75% without
affecting the alprenolol’s half-life, it did not
significantly affect the AUC or half-life of the drug
after its intravenous administration.
As for Qh, in contrast to the low Eh drugs, the
pharmacokinetics of high Eh drugs are affected by
changes in this parameter after both intravenous and
oral administration. As shown in Table 2, doubling
Qh hardly affects the Eh value but almost doubles the
Fh and Clh of the drug. Therefore, the blood
concentration-time course of the drug after the
intravenous administration shows a 50% reduction in
the AUC and half-life (Fig. 4C). The oral profile
would be affected by changes in both Cl and Fh (Fig.
4D). After oral dosing, an increase in Cl due to an
increase in Qh causes a proportional reduction in
AUC and shortening of half-life. However, an
increase in Qh also proportionally increases Fh (𝐹 ≈
) and AUC. Therefore, as demonstrated in Fig.
4D, the AUC after oral dosing remains the same.
Please note that the above discussions are based on
the well-stirred model, which predicts that oral AUC
is not dependent on Qh for drugs that are eliminated
by hepatic metabolism:
𝐴𝑈𝐶

=

∙

(25)

In the above equation, an increase in Qh causes
proportional increases in both Cl and F, without any
significant changes in the AUC for a drug with high
Eh.

Table 2. The pharmacokinetic parameters of a hypothetical druga with high hepatic extraction ratio (Eh) in the absence
(Control) and presence of changes in the intrinsic capability of the liver to remove the free drug (Cl’int), free drug fraction
in blood (fub), or hepatic blood flow (Qh)
Condition
Cl’int
fub
Clint (L/h)
Qh
Ehb
Fhb
Clhb
V
t1/2c
(L/h)
(L/h)
(L/h)
(L)
(h)
Control
15000
0.1
1500
90
0.943
0.0566
84.9
400
3.26
30000
0.1
3000
90
0.971
0.0291
87.4
400
3.17
 Cl’int x 2
15000
0.2
3000
90
0.971
0.0291
87.4
400
3.17
 fub x 2
15000
0.1
1500
180
0.893
0.107
161
400
1.72
 Qh x 2
a
The hypothetical drug has a Cl’int of 15000 L/h, a fub of 0.1, and a volume of distribution (V) of 400 L under baseline
conditions, with elimination through the liver only.
b
Eh, Fh, and Clh were estimated from the values of Cl’int, fub, and Qh using Equations 9, 4, and 3, respectively.
.
×
c
Half-life (t1/2) is estimated from 𝑡 / =
, where Cl is assumed to be equal to Clh.
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(C)

(D)
0.1
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1
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0.1

0.01

High E-Control
Increased Qh
0

4
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0.01

0.001

12

Time (Hours)

High E-Control
Increased Qh
0

4

8

12
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Figure 4. Effects of a two-fold increase in Clint (fub or Cl’int) (top panels) or Qh (bottom panels) on the blood concentrationtime courses of a hypothetical high Eh drug after intravenous (left) or oral (right) administration of a 400-mg dose of the drug.
The kinetic parameters are listed in Table 2.

An example of the effects of changes in the blood
flow on the pharmacokinetics in the literature is
related to the interaction of lidocaine, a high Eh drug,
with metoprolol and propranolol, which reduce the
cardiac output and hepatic blood flow (22).
Lidocaine was administered by a short intravenous
infusion alone or 1 day after pretreatment with
metoprolol (50 mg orally every 6 h) or propranolol
(40 mg orally every 6 h). Metoprolol and propranolol
reduced the clearance of intravenous lidocaine by
30% and 50% respectively, presumably due to their
effects on the hepatic blood flow.

It should be noted that the changes in the
clearance, in addition to affecting the half-life of the
drug, also affects the maximum plasma
concentration (Cmax) and the time to reach Cmax for
orally-administered drug.
Oral Clearance and Intrinsic Clearance
The well-stirred model predicts that the oral
clearance (Clo or Cl/F) of a drug with hepatic
elimination alone and no loss in the gastrointestinal
tract (F = Fh) is in fact equal to its Clint (𝑓 ∙ 𝐶𝑙 ),
therefore, being independent of Qh regardless of
drug’s Eh:
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𝐶𝑙 =

=
𝐶𝑙

=

=𝑓

×

would be accurate only if the blood: plasma
concentration (B:P) ratio of the drug is equal to 1.
However, the use of the plasma concentrations and
plasma liver flow will always result in an
overestimation of the true Eh unless the drug does not
penetrate the red blood cells (23).

×

=

=
(26)

∙ 𝐶𝑙

Consequently, it is not surprising that the oral AUC
is not affected by Qh, as shown in Figs. 3D and 4D
for the low and high Eh drugs, respectively. Even if
the Fab and/or Fg values are significantly lower than
1, Clo is still a function of Clint (and not Qh) as shown
below:
𝐶𝑙 =

=

×
× ×

=
×

Prediction of Oral Bioavailability from Oral
Data Only
In some cases, administration of a drug by
intravenous method is not feasible or an injectable
dosage form is not available. Using the clearance
concepts, and some assumptions, it is possible to
obtain a rough estimate of the extent of oral
bioavailability of drugs using oral data only. We
reported (24) the oral clearance (Clo) of
tetrabenazine, a drug used for the control of
movement disorders, in four patients with tardive
dyskinesia. The Clo values were estimated by
dividing the oral dose by the AUC. We then used the
following equation, which is based on Equations 10
and 26 to estimate Fh in these patients, assuming a
hepatic blood flow of 1.28 (L/h)/kg and complete
oral absorption and intestinal availability (i.e., 𝐹 =
𝐹 ):

×

=

×

×

=

(27)

EXAMPLES OF APPLICATION OF
CLEARNCE CONCEPTS IN
INTERPRETATION OF
PHARMACOKINETIC BEHAVIOR OF
DRUGS
Estimation of Hepatic Extraction Ratio of Drugs
from In Vivo Pharmacokinetic Data
Equation 3 may be rearranged to estimate Eh of a
drug after its intravenous administration:
𝐸 =

𝐹=𝐹 =

(29)

=

The estimated F values were 0.05, 0.08, 0.07,
and 0.02 for patients with Clo values of 431, 252, 299,
and 1090 (ml/min)/kg, respectively (24). Based on
these values, we suggested that the oral
bioavailability (F) of tetrabenazine in humans is very
low. Indeed, the F value obtained in another study
(25) after the intravenous and oral administration of
the drug to humans (0.05) was very close to the
values obtained from the oral data alone.
It should be noted that these calculations assume
elimination by the liver alone (i.e., no renal or
gastrointestinal clearance). However, a modified
version of Equation 29 may be provided for drugs
with both renal and hepatic clearance pathways, as
shown below:

(28)

After intravenous administration of the drug, the
systemic Cl is estimated from the blood
concentration-time data, and an estimate of Clh is
obtained by either assuming Clh is equal to systemic
clearance (i.e., for drugs with hepatic elimination
only) or by subtracting renal Cl from the systemic
clearance (i.e., for drugs with both renal and hepatic
elimination), as discussed in detail recently (23). An
estimate of Eh is then obtained using the calculated
Clh and an average Qh. The estimates of Eh value can
then be used to predict the pharmacokinetics and
blood concentration-time profiles of the drug in the
presence of changes in the physiologic determinants
of clearance such as organ blood flow, intrinsic
clearance, or fub. The assumptions inherent to this
type of calculation and the ramifications of using
plasma or serum concentrations, instead of blood
concentrations, and/or liver plasma flow, instead of
liver blood flow, were recently discussed in detail
(23). Briefly, it was shown that if plasma clearance
and hepatic blood flow are used, the estimated Eh

𝐶𝑙 =
×(

=
)

=

=

𝐶𝑙 × 𝐹 = 𝐶𝑙 + 𝑄 − 𝑄 𝐹
𝐹 (𝐶𝑙 + 𝑄 ) = 𝐶𝑙 + 𝑄
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The systemic clearance of cyclosporine based on the
intravenous dose of 3 mg/kg and AUCiv of 10092
was 0.3 L/kg:

(33)

𝐹 =

After determination of Clr and Clo, Equation 33 may
be used to estimate Fh (or F) for drugs with both
hepatic and renal elimination.

𝐶𝑙 =

Differentiation of Gut and Hepatic First-Pass
Metabolism of Drugs
An application of clearance concept in the literature
is for differentiation of first-pass metabolism in the
gut from that in the liver. After oral administration,
the oral bioavailability of a drug (F) is a function of
the fraction of the drug absorbed (Fab), fraction of the
drug escaping metabolism in the gastrointestinal
tract (Fg), and fraction of the drug escaping the
hepatic metabolism or hepatic availability (Fh), as
demonstrated in Fig. 2 and Equation 24. Once a drug
is administered by both oral and intravenous routes,
F may be estimated from the oral and intravenous
AUC values (correcting for the dose). Additionally,
the hepatic Eh and Fh may be estimated from the
intravenous data using Equations 28 and 4,
respectively, assuming an average Qh of 1500
mL/min in a 70-kg subject. Consequently, the value
of 𝐹 × 𝐹 may be estimated from the F and Fh
values by rearranging Equation 24:
𝐹

×𝐹 =

Assuming the systemic clearance of cyclosporine is
equal to its hepatic clearance (i.e., gut clearance
doses not significantly contribute to the systemic
clearance) and a Qh of 1.286 L/h/kg (90 L/h in a 70kg subject), the Eh and Fh values were then
estimated:
0.3
= 0.23
1.286
𝐹 = 1 − 0.23 = 0.77
𝐸 =

Using the predicted Fh and measured F, the 𝐹
value of cyclosporine was then determined:
𝐹

𝐹=

×

×𝐹 =

×𝐹

𝐹
0.27
=
= 0.35
𝐹
0.77

A comparison of F (0.27), Fh (0.77), and 𝐹 × 𝐹
(0.35) values of cyclosporine in these patients,
clearly suggests that the low oral bioavailability of
the drug is mostly due to the loss of drug in the
gastrointestinal tract than its loss during the first-pass
metabolism in the liver. Later, Galetin et al. (27) used
this method to estimate the Fg of a number of drugs,
with an assumption that the absorption of the drugs,
if experimentally unknown, was complete (Fab = 1).

(34)

This method allows one to separate the contribution
of the liver (Fh) from that of the gut (𝐹 × 𝐹 ) to the
overall loss of the drug after the oral administration.
However, in the absence of any additional
information about the extent of absorption of the
drug, Fab and Fg cannot be separated from each other.
An application of this method was demonstrated
by Hebert et al. (26), who administered a single oral
(10 mg/kg) or intravenous (3 mg/kg) dose of
cyclosporine to six healthy subjects and found
average blood AUC values of 8986 and 10092
ng.h/mL, respectively. Based on the oral and
intravenous data, the oral bioavailability (F) of
cyclosporine in these patients was 0.27:
𝐹=

𝐷𝑜𝑠𝑒
3000
=
= 0.3 L/kg
𝐴𝑈𝐶
10092

Differentiation of Incomplete Absorption from
the First-Pass Metabolism in the Gut and Liver
Wu et al. (19) proposed a method to determine Fab,
Fg, and Fh separately, based on the intravenous and
oral administration of a drug in the absence and
presence of interacting drugs known to inhibit its
metabolism. If the interacting and victim drugs are
administered several hours apart from each other,
one may assume that the interacting drug would only
affect the metabolism and not the extent of
absorption of the victim drug. In that case, the
following equations may be defined:

(35)

𝐹 = 𝐹 ×𝐹 ×𝐹
In the Absence of Interaction

8986
3
×
= 0.27
10092 10

𝐹 = 𝐹 ×𝐹 , ×𝐹 ,
In the Presence of Interaction
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where the subscript itx indicates the parameter in
the presence of the interacting drug. The values of
𝐹 × 𝐹 or 𝐹 × 𝐹 ,
may be easily estimated
from F and Fh or Fitx and Fh,itx, respectively, using
Equation 34.
In the case of an enzyme inhibitor interaction,
the value of Fab may be estimated between its two
minimum and maximum boundaries. The maximum
boundary of Fab is 1. The minimum boundary of Fab
is assuming Fg,itx is equal to 1 (i.e., complete
inhibition of gut metabolism). Setting Fab to its
maximum (i.e., 1) or minimum (calculated from the
enzyme inhibition data) boundaries, the values of Fg
in control subjects (i.e., the absence of drug
interaction) may be estimated between a minimum
and a maximum.
The method was used to determine the
contribution of hepatic and gastrointestinal first-pass
metabolism to the overall F of cyclosporine in the
presence and absence of two enzyme inhibitors
(erythromycin and ketoconazole) and an enzyme
inducer (rifampin) (19). Here, we present the data
(28) and calculations (19) for the ketoconazole
inhibition study, which was conducted in five
healthy subjects. The doses and average blood AUC
values after the oral and intravenous administration
of cyclosporine in the absence (Control) and
presence of ketoconazole are listed in Table 3 (28).
Using the average values presented in Table 3,
The F, Fh, and 𝐹 × 𝐹 values in Control subjects
may be estimated as shown below:
𝐹=

𝐴𝑈𝐶
𝐴𝑈𝐶

𝐶𝑙 =

×

𝐷𝑜𝑠𝑒
𝐷𝑜𝑠𝑒

𝐹

×𝐹 =

× 𝐹 = 0.290
𝐹 =

0.290
𝐹

𝐹

=

0.290
= 0.290
1

𝐹

=

0.290
= 0.402
0.722

Therefore, the lower ( 𝐹
) and upper
(𝐹
) limits of Fg for cyclosporine in healthy
volunteers are 0.290 and 0.402, whereas the lower
and upper limits of Fab are 0.722 and 1, respectively.
Considering an Fh of 0.766 (Table 4), the data
suggest that the low oral bioavailability of
cyclosporine in Control subjects (0.222) is indeed
mostly due to its first-pass metabolism in the gut (Fg
of 0.290-0.402), whereas the oral absorption of the
formulation is relatively high (Fab of 0.722-1.0).
Again, these calculations assume that gut clearance,
although reducing the presystemic availability of the
drug, does not significantly contribute to the
systemic clearance of the drug, meaning that Cl is
equal to Clh.
More recently, Hisaka et al. (29) developed a
new method based on the concept of drug-drug
interactions to estimate Fg values from the changes
in the AUC and half-life values of the victim drug in
the presence of the perpetrating drug. The method is
based on the idea that the inhibition of intestinal
metabolism causes a change in the AUC without any
changes in the plasma half-life. However, inhibition
of hepatic metabolism results in changes in both halflife and AUC, unless the clearance of the drug is
flow-limited (i.e., drugs with high extraction ratio).
Nevertheless, the method still requires an
approximation of Fab value. Using this method, the
authors estimated Fg values of 0.56 ± 0.29 (mean ±
SD) for 20 drugs that were CYP3A substrates and
0.86 ± 0.11 for 8 drugs that were not CYP3A
substrates. The interested readers are referred to the
original article (29) for details about the method and
derivation of equations.

5938 0.5
×
= 0.222
6683
2

𝐷𝑜𝑠𝑒
2000
=
= 0.299 𝐿/ℎ/𝑘𝑔
𝐴𝑈𝐶
6683

𝐹 =1−𝐸 =1−

𝐹

=

The data in the presence of ketoconazole,
presented in Table 4, suggest that two boundaries of
Fab are 1 and 0.722. Consequently, Fg may be
estimated at these two boundaries:

𝐶𝑙
0.299
=1−
= 1 − 0.234
𝑄
1.28
= 0.766
𝐹
0.222
=
= 0.290
𝐹
0.766

Similarly, Fitx, Fh,itx, and 𝐹 × 𝐹 , in the presence
of ketoconazole may be calculated using the
respective data in Table 3. The summary of the above
calculations, based on the average AUC value
reported before (28), are presented in Table 4.
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Table 3. The dose and average AUC values of cyclosporine after intravenous and oral administration of the drug to healthy
subjects in the absence (Control) and presence of ketoconazolea
Dose, mg/kg
AUC, ng.h/mL
Intravenous
Oral
Intravenous
Oral
Control
2
8
6683
5938
Plus Ketoconazole
0.5
2
3120
7883
a
Data from reference (28).

Table 4. The calculated oral bioavailability (F) and estimated hepatic availability (Fh) and products of fraction absorbed
(Fab) and gut availability (Fg) of cyclosporine in the absence (Control) and presence of ketoconazolea
F
Fh
Fab . Fg
Control
0.222
0.766
0.290
Plus Ketoconazole
0.632
0.875
0.722
a
Calculations are based on the average AUC values and doses presented in Table 3.

Estimation of Gastrointestinal Availability from
Grapefruit Juice-Drug Interaction Studies
Grapefruit juice (GFJ) components are believed to
irreversibly inhibit intestinal CYP3A4, without any
major effect on the liver CYP3A4 (30). Therefore,
co-administration of grapefruit juice with an orallyadministered drug that is subject to intestinal
CYP3A4 metabolism inhibits the drug’s CYP3A4mediated, presystemic intestinal metabolism. Gertz
et al. (31) used available data in the literature related
to the interaction of drugs with grapefruit juice to
estimate their Fg, using the following equation:
𝐹 =

number of assumptions, hence subject to some
degree of error. First, the AUC and clearance terms
in the above equations are based on the blood
concentrations of the drug. Therefore, the use of
plasma values, which are commonly measured, may
introduce substantial errors in the estimation of the
kinetic parameters (23). Second, a number of
calculations listed above use an average liver blood
flow (e.g., 1500 mL/min), which might be different
than the actual Qh in the studied subjects. This is
because although intraand inter-individual
variabilities in the hepatic blood flow in healthy
subjects under controlled conditions appears to be
relatively low (32-34), physiological factors (e.g.,
posture and exercise), pharmacological interventions
(e.g., beta-blockers), disease states (e.g., heart
failure), or food ingestion may significantly affect
hepatic blood flow (35, 36). Other assumptions
include linear pharmacokinetics and a constant
systemic clearance after different routes of
administration. With specific reference to methods
estimating Fg, additional assumptions are that the
intestinal clearance, although reducing the
presystemic availability of the drug, does not
significantly contribute to the systemic clearance of
the drug. Lastly, estimation of Fg is also based on the
assumption that the drug is not subject to influx or
efflux transporters. Nevertheless, despite these
assumptions and/or limitations, application of
clearance concepts has resulted in substantial
improvement in our understanding of the
pharmacokinetics of many drugs.

(36)

where AUCControl and AUCGFJ are the AUC of the
drug in the absence and presence of GFJ
administration, respectively. This method assumes
complete intestinal metabolism of the drug through
CYP3A4, complete inhibition of intestinal
metabolism with GFJ, and no effect of GFJ on the
systemic (liver) metabolism or clearance or the
extent of absorption (Fab) of the drug. Additionally,
the authors (31) suggested that the method’s
applicability to drugs that are subject to transport or
efflux in the gastrointestinal tract is limited.
LIMITATIONS
It should be noted that while clearance concepts are
very useful in predicting the pharmacokinetic
behavior of drugs, their applications to estimation of
F and its components (Fab, Fg, and Fh) in different
situations presented here are associated with a
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CONCLUSIONS

8.

In conclusion, development of clearance concepts
has significantly moved the discipline of
pharmacokinetics forward. Although clearance
concepts are more discussed in terms of hepatic
clearance, they are equally applicable to clearance by
other eliminating organs, such as the kidneys. The
concepts allow definition of organ and total
clearance values in terms of physiologic parameters
such as organ blood flow and intrinsic capability of
the eliminating organ to remove the drug from the
body. Furthermore, the clearance concepts allow
prediction of the pharmacokinetics of drugs after
intra- and extravascular routes in the presence of
disease states, drug interactions, or as a result of
patients’ age. Researchers have applied these
concepts to predict the oral bioavailability of drugs
in the absence of otherwise needed intravenous data,
to distinguish between the role of liver and gut in the
first pass metabolism of drugs, and to differentiate
between the incomplete oral absorption and
metabolism in the gut after oral administration of
drugs. More than 45 years after their introduction,
clearance concepts remain a powerful tool in
explaining the pharmacokinetics of drugs and
predicting the changes in the blood concentrationtime course of drugs when the underlying
physiologic parameters are altered.

9.

10.

11.
12.
13.

14.
15.

REFERENCES
1.
2.
3.
4.
5.
6.
7.

Gillette JR. Factors affecting drug metabolism. Ann
N Y Acad Sci. 1971;179:43-66.
Rowland M, Benet, L.Z., Grahm, G.G. Clearance
concepts in pharmacokinetics. J Pharmacokinet
Biopharm. 1973;1:123-36.
Wilkinson G, Shand D. A physiological approach to
hepatic drug clearance. Clin Pharmacol Ther.
1975;18:377-89.
Benet LZ. Clearance (nee Rowland) concepts: a
downdate and an update. J Pharmacokinet
Pharmacodyn. 2010;37:529-39.
Mehvar R. Interdependency of pharmacokinetic
parameters: a chicken-and-egg problem? Not! J
Pharm Pharm Sci. 2006;9:113-8.
Sirianni GL, Pang KS. Organ clearance concepts:
New perspectives on old principles. J Pharmacokinet
Biopharm. 1997;25:449-70.
Pang KS, Weiss M, Macheras P. Advanced
pharmacokinetic models based on organ clearance,
circulatory, and fractal concepts. AAPS J.
2007;9:E268-83.

16.

17.

18.

19.

20.

101s

Pang K, Rowland M. Hepatic clearance of drugs. I.
Theoretical considerations of a "well-stirred" model
and a "parallel tube" model. Influence of hepatic
blood flow, plasma and blood cell binding, and the
hepatocellular enzymatic activity on hepatic drug
clearance. J Pharmacokinet Biopharm. 1977;5:62553.
Pang K, Rowland M. Hepatic clearance of drugs. II.
Experimental evidence for acceptance of the "wellstirred" model over the "parallel tube" model using
lidocaine in the perfused rat liver in situ preparation.
J Pharmacokinet Biopharm. 1977;5:655-79.
Pang K, Rowland M. Hepatic clearance of drugs. III.
Additional experimental evidence supporting the
"well-stirred" model, using metabolite (MEGX)
generated from lidocaine under varying hepatic blood
flow rates and linear conditions in the perfused rat
liver in situ preparation. J Pharmacokinet Biopharm.
1977;5:681-99.
Roberts M, Rowland M. Hepatic elimination-dispersion model. J Pharm Sci. 1985;74:585-7.
Gray M, Tam Y. The series-compartment model for
hepatic elimination. Drug Metab Disposit.
1986;15:27-31.
Pang KS, Terrell JA, Nelson SD, Feuer KF, Clements
MJ, Endrenyi L. An enzyme-distributed system for
lidocaine metabolism in the perfused rat liver
preparation.
J
Pharmacokinet
Biopharm.
1986;14:107-30.
Bass L, Robinson P, Bracken AJ. Hepatic elimination
of flowing substrates: the distributed model. J Theor
Biol. 1978;72:161-84.
Goresky CA, Bach GG, Nadeau BE. On the uptake of
materials by the intact liver. The transport and net
removal of galactose. J Clin Invest. 1973;52:9911009.
Yamazaki M, Akiyama S, Nishigaki R, Sugiyama Y.
Uptake is the rate-limiting step in the overall hepatic
elimination of pravastatin at steady state in rats.
Pharm Res. 1996;13:1559-64.
Benet LZ, Liu S, Wolfe AR. The universally
unrecognized assumption in predicting drug
clearance and organ extraction ratio. Clin Pharmacol
Ther. 2018;103:521-5.
Rowland M, Pang KS. Commentary on "The
universally unrecognized assumption in predicting
drug clearance and organ extraction ratio". Clin
Pharmacol Ther. 2018;103:386-8.
Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland
M, Gomez DY, et al. Differentiation of absorption
and first-pass gut and hepatic metabolism in humans:
Studies with cyclosporine. Clin Pharmacol Ther.
1995;58:492-7.
O'Reilly RA. Interaction of sodium warfarin and
rifampin. Studies in man. Ann Intern Med.
1974;81:337-40.

J Pharm Pharm Sci (www.cspsCanada.org) 21, 88s - 102s, 2018

21. Alvan G, Piafsky K, Lind M, von Bahr C. Effect of
pentobarbital on the disposition of alprenolol. Clin
Pharmacol Ther. 1977;22:316-21.
22. Conrad KA, Byers JM, 3rd, Finley PR, Burnham L.
Lidocaine elimination: effects of metoprolol and of
propranolol. Clin Pharmacol Ther. 1983;33:133-8.
23. Mehvar R. Application of organ clearance to
estimation of the in vivo hepatic extraction ratio. Curr
Clin Pharmacol. 2016;11:47-52.
24. Mehvar R, Jamali F, Watson M, Skelton D.
Pharmacokinetics of tetrabenazine and its major
metabolite in man and rat: bioavailability and dose
dependency studies. Drug Metab Disposit.
1987;15:250-5.
25. Roberts MS, McLean S, Millingen KS, Galloway HM.
The pharmacokinetics of tetrabenazine and its
hydroxy metabolite in patients treated for involuntary
movement disorders. Eur J Clin Pharmacol.
1986;29:703-8.
26. Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ.
Bioavailability of cyclosporine with concomitant
rifampin administration is markedly less than
predicted by hepatic enzyme induction. Clin
Pharmacol Ther. 1992;52:453-7.
27. Galetin A, Gertz M, Houston JB. Potential role of
intestinal first-pass metabolism in the prediction of
drug-drug interactions. Expert Opin Drug Metab
Toxicol. 2008;4:909-22.
28. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF,
Benet LZ. The effects of ketoconazole on the
intestinal metabolism and bioavailability of
cyclosporine. Clin Pharmacol Ther. 1995;58:15-9.

29. Hisaka A, Nakamura M, Tsukihashi A, Koh S, Suzuki
H. Assessment of intestinal availability (FG) of
substrate drugs of cytochrome p450s by analyzing
changes in pharmacokinetic properties caused by
drug-drug interactions. Drug Metab Dispos.
2014;42:1640-5.
30. Bailey DG, Malcolm J, Arnold O, Spence JD.
Grapefruit juice-drug interactions. Br J Clin
Pharmacol. 1998;46:101-10.
31. Gertz M, Davis JD, Harrison A, Houston JB, Galetin
A. Grapefruit juice-drug interaction studies as a
method to assess the extent of intestinal availability:
utility and limitations. Curr Drug Metab. 2008;9:78595.
32. Soons PA, De Boer A, Cohen AF, Breimer DD.
Assessment of hepatic blood flow in healthy subjects
by continuous infusion of indocyanine green. Br J
Clin Pharmacol. 1991;32:697-704.
33. Richardson PD, Withrington PG. Liver blood flow. I.
Intrinsic and nervous control of liver blood flow.
Gastroenterology. 1981;81:159-73.
34. Carlisle KM, Halliwell M, Read AE, Wells PN.
Estimation of total hepatic blood flow by duplex
ultrasound. Gut. 1992;33:92-7.
35. Daneshmend TK, Jackson L, Roberts CJ.
Physiological and pharmacological variability in
estimated hepatic blood flow in man. Br J Clin
Pharmacol. 1981;11:491-6.
36. McLean AJ, McNamara PJ, duSouich P, Gibaldi M,
Lalka D. Food, splanchnic blood flow, and
bioavailability of drugs subject to first-pass
metabolism. Clin Pharmacol Ther. 1978;July:5-10.

102 s

